Biomedica produces therapeutic protein in eggs

Shares of the UK's Oxford Biomedica surged in overnight trading after the biotech reported that its collaboration to produce drugs in genetically modified chickens had achieved success in producing a potentially effective protein in the whites of an egg. Biomedica has been working with Viragen and the Roslin Institute to make antibodies and proteins in agricultural products like milk and eggs. The biotech also said that a preclinical test of its experimental treatment Innurex showed that it was able to produce some nerve repair in spinal cord damage.

"We have long believed that this joint effort would develop an avian system capable of efficiently and economically producing human biopharmaceuticals, and with this major milestone achievement, I am even more convinced that we are developing an elite manufacturing platform that should emerge as a method of choice for many products," said the project's scientific leader, Roslin Senior Scientist Dr. Helen Sang.

- read this press release for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.